Progress and pitfalls in defining the influence of highly active antiretroviral therapy on human papillomavirus-associated cervical disease.
Gravitt
Patti E
PE
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21231, USA. pgravitt@jhsph.edu
Kirk
Gregory D
GD
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D030361:Papillomavirus Infections / Q000453:epidemiology* / Q000821:virology; D015995:Prevalence; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000821:virology
D019380:Anti-HIV Agents